These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20043166)

  • 21. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
    Reck M; Frickhofen N; Cedres S; Gatzemeier U; Heigener D; Fuhr HG; Thall A; Lanzalone S; Stephenson P; Ruiz-Garcia A; Chao R; Felip E
    Lung Cancer; 2010 Nov; 70(2):180-7. PubMed ID: 20188433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
    J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
    Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
    Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
    Sonpavde G; Periman PO; Bernold D; Weckstein D; Fleming MT; Galsky MD; Berry WR; Zhan F; Boehm KA; Asmar L; Hutson TE
    Ann Oncol; 2010 Feb; 21(2):319-324. PubMed ID: 19633050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of sunitinib in men with advanced prostate cancer.
    Dror Michaelson M; Regan MM; Oh WK; Kaufman DS; Olivier K; Michaelson SZ; Spicer B; Gurski C; Kantoff PW; Smith MR
    Ann Oncol; 2009 May; 20(5):913-20. PubMed ID: 19403935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
    Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
    Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K; Yoda K; Tomoishi J; Kume H
    BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
    Okamoto I; Shimizu T; Miyazaki M; Tsurutani J; Ichikawa Y; Terashima M; Takeda M; Fumita S; Ohki E; Kimura N; Hashimoto J; Nakagawa K
    Invest New Drugs; 2012 Apr; 30(2):639-46. PubMed ID: 20960028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
    Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
    Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
    Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
    Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
    Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
    Masters GA; Brockstein BE; Mani S; Ratain MJ
    Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
    Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
    Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.